BAKER BROS. ADVISORS LP Q4 2017 Filing
Filed February 14, 2018
Portfolio Value
$11.5B
Holdings
123
Report Date
Q4 2017
Filing Type
13F-HR
All Holdings (123 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Ra Pharmaceuticals, Inc. | 177,952 | $1.5B | 13.11% | |
| 102 | CLLSCellectis S.A. | 50,000 | $1.5B | 12.64% | |
| 103 | DVAXDynavax Technologies Corporation | 75,000 | $1.4B | 12.16% | |
| 104 | —Achaogen, Inc. | 122,482 | $1.3B | 11.40% | |
| 105 | JNCEEURJounce Therapeutics, Inc. | 100,000 | $1.3B | 11.05% | |
| 106 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $1.2B | 10.21% | |
| 107 | —MediWound Ltd. | 226,000 | $1.0B | 8.72% | |
| 108 | —Ritter Pharmaceuticals, Inc. | 2,800,000 | $922.0M | 7.99% | |
| 109 | I9DNArbutus Biopharma Corporation | 180,582 | $912.0M | 7.90% | |
| 110 | —Molecular Templates, Inc. | 72,412 | $726.0M | 6.29% | |
| 111 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $668.0M | 5.79% | |
| 112 | —BioDelivery Sciences International, Inc. | 210,021 | $620.0M | 5.37% | |
| 113 | —Immune Design Corp. | 148,937 | $581.0M | 5.04% | |
| 114 | —Proteon Therapeutics, Inc. | 298,591 | $567.0M | 4.91% | |
| 115 | FLGTFulgent Genetics, Inc. | 125,000 | $548.0M | 4.75% | |
| 116 | —Affimed N.V. | 400,000 | $520.0M | 4.51% | |
| 117 | —Five Prime Therapeutics, Inc. | 19,247 | $422.0M | 3.66% | |
| 118 | —T2 Biosystems, Inc. | 100,000 | $412.0M | 3.57% | |
| 119 | CCXIEURChemoCentryx, Inc. | 49,064 | $292.0M | 2.53% | |
| 120 | —InVivo Therapeutics Holdings Corp. | 331,393 | $255.0M | 2.21% | |
| 121 | —Tenax Therapeutics, Inc. | 348,374 | $171.0M | 1.48% | |
| 122 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $92.0M | 0.80% | |
| 123 | —BioTime, Inc. | 20,084 | $2.0M | 0.02% |
PreviousPage 2 of 2